Table 1.
Dyskinesia therapies in the clinic
| ORGANISATION | THERAPY | MODE OF ACTION | CLINICAL STAGE |
| Addex Therapeutics | Dipraglurant | mGluR5 negative allosteric modulator | Phase 2 (complete) |
| Coeptis/Elto Pharma | Eltoprazine | 5HT 1A/1B partial agonist | Phase 2 |
| Hôpitaux de Paris | Buspirone | 5-HT1A agonist | Phase 3 |
| Contera/Bukwang | JM-010 (buspirone and zolmitriptan) | 5-HT1A agonist and 5-HT1B/5-HT1D agonist combination | Phase 2 |
| Oregon University | Buspirone and amantadine | 5-HT1A agonist and NMDA inhibitor combination | Phase 2 |
| Integrative Research Laboratories | IRL-790 | Dopamine D3 receptor antagonist | Phase 2 |
| Prilenia | Pridopidine | Sigma-1 receptor inhibitor | Phase 2 |
| Trevi Therapeutics | Nalbuphine | Opioid μ antagonist/ κ agonist | Phase 1 |